FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946327> ?p ?o ?g. }

• W4361946327 abstract "<div>AbstractPurpose:<p>Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, for first-line treatment of <i>EGFR</i>-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described.</p>Experimental Design:<p>Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients.</p>Results:<p>In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, <i>P</i> = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, <i>P</i> = 0.02).</p>Conclusions:<p>Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients.</p><p><i>See related commentary by Devarakonda and Govindan, p. 6112</i>.</p></div>" @default.
• W4361946327 created "2023-04-05" @default.
• W4361946327 creator A5007121755 @default.
• W4361946327 creator A5007462622 @default.
• W4361946327 creator A5008790176 @default.
• W4361946327 creator A5022433974 @default.
• W4361946327 creator A5022661673 @default.
• W4361946327 creator A5023878847 @default.
• W4361946327 creator A5024457228 @default.
• W4361946327 creator A5025095617 @default.
• W4361946327 creator A5027152610 @default.
• W4361946327 creator A5029399672 @default.
• W4361946327 creator A5037889591 @default.
• W4361946327 creator A5040693824 @default.
• W4361946327 creator A5048380048 @default.
• W4361946327 creator A5059588535 @default.
• W4361946327 creator A5060262778 @default.
• W4361946327 creator A5070183988 @default.
• W4361946327 creator A5072939839 @default.
• W4361946327 creator A5073466449 @default.
• W4361946327 creator A5074756797 @default.
• W4361946327 creator A5076621000 @default.
• W4361946327 creator A5077641115 @default.
• W4361946327 creator A5079954554 @default.
• W4361946327 creator A5088412190 @default.
• W4361946327 creator A5089451206 @default.
• W4361946327 date "2023-03-31" @default.
• W4361946327 modified "2023-09-27" @default.
• W4361946327 title "Data from Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC" @default.
• W4361946327 doi "https://doi.org/10.1158/1078-0432.c.6526994" @default.
• W4361946327 hasPublicationYear "2023" @default.
• W4361946327 type Work @default.
• W4361946327 citedByCount "0" @default.
• W4361946327 crossrefType "posted-content" @default.
• W4361946327 hasAuthorship W4361946327A5007121755 @default.
• W4361946327 hasAuthorship W4361946327A5007462622 @default.
• W4361946327 hasAuthorship W4361946327A5008790176 @default.
• W4361946327 hasAuthorship W4361946327A5022433974 @default.
• W4361946327 hasAuthorship W4361946327A5022661673 @default.
• W4361946327 hasAuthorship W4361946327A5023878847 @default.
• W4361946327 hasAuthorship W4361946327A5024457228 @default.
• W4361946327 hasAuthorship W4361946327A5025095617 @default.
• W4361946327 hasAuthorship W4361946327A5027152610 @default.
• W4361946327 hasAuthorship W4361946327A5029399672 @default.
• W4361946327 hasAuthorship W4361946327A5037889591 @default.
• W4361946327 hasAuthorship W4361946327A5040693824 @default.
• W4361946327 hasAuthorship W4361946327A5048380048 @default.
• W4361946327 hasAuthorship W4361946327A5059588535 @default.
• W4361946327 hasAuthorship W4361946327A5060262778 @default.
• W4361946327 hasAuthorship W4361946327A5070183988 @default.
• W4361946327 hasAuthorship W4361946327A5072939839 @default.
• W4361946327 hasAuthorship W4361946327A5073466449 @default.
• W4361946327 hasAuthorship W4361946327A5074756797 @default.
• W4361946327 hasAuthorship W4361946327A5076621000 @default.
• W4361946327 hasAuthorship W4361946327A5077641115 @default.
• W4361946327 hasAuthorship W4361946327A5079954554 @default.
• W4361946327 hasAuthorship W4361946327A5088412190 @default.
• W4361946327 hasAuthorship W4361946327A5089451206 @default.
• W4361946327 hasBestOaLocation W43619463272 @default.
• W4361946327 hasConcept C121608353 @default.
• W4361946327 hasConcept C126322002 @default.
• W4361946327 hasConcept C143998085 @default.
• W4361946327 hasConcept C2775999482 @default.
• W4361946327 hasConcept C2776256026 @default.
• W4361946327 hasConcept C2777626846 @default.
• W4361946327 hasConcept C2777930144 @default.
• W4361946327 hasConcept C2779256057 @default.
• W4361946327 hasConcept C2781182431 @default.
• W4361946327 hasConcept C502942594 @default.
• W4361946327 hasConcept C71924100 @default.
• W4361946327 hasConceptScore W4361946327C121608353 @default.
• W4361946327 hasConceptScore W4361946327C126322002 @default.
• W4361946327 hasConceptScore W4361946327C143998085 @default.
• W4361946327 hasConceptScore W4361946327C2775999482 @default.
• W4361946327 hasConceptScore W4361946327C2776256026 @default.
• W4361946327 hasConceptScore W4361946327C2777626846 @default.
• W4361946327 hasConceptScore W4361946327C2777930144 @default.
• W4361946327 hasConceptScore W4361946327C2779256057 @default.
• W4361946327 hasConceptScore W4361946327C2781182431 @default.
• W4361946327 hasConceptScore W4361946327C502942594 @default.
• W4361946327 hasConceptScore W4361946327C71924100 @default.
• W4361946327 hasLocation W43619463271 @default.
• W4361946327 hasLocation W43619463272 @default.
• W4361946327 hasOpenAccess W4361946327 @default.
• W4361946327 hasPrimaryLocation W43619463271 @default.
• W4361946327 hasRelatedWork W2765285169 @default.
• W4361946327 hasRelatedWork W2888286093 @default.
• W4361946327 hasRelatedWork W2921871143 @default.
• W4361946327 hasRelatedWork W2944874515 @default.
• W4361946327 hasRelatedWork W2985223206 @default.
• W4361946327 hasRelatedWork W3013327955 @default.
• W4361946327 hasRelatedWork W3137075329 @default.
• W4361946327 hasRelatedWork W3206265110 @default.
• W4361946327 hasRelatedWork W3213559286 @default.
• W4361946327 hasRelatedWork W4296767431 @default.
• W4361946327 isParatext "false" @default.
• W4361946327 isRetracted "false" @default.
• W4361946327 workType "article" @default.